Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Toon Min is active.

Publication


Featured researches published by Toon Min.


British Journal of Haematology | 1997

Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia

Lynne R. Hiorns; G. John Swansbury; Jayesh Mehta; Toon Min; Melissa Dainton; Jennie Treleaven; R. Powles; Daniel Catovsky

Acute promyelocytic leukaemia (APL) has been associated with a favourable prognosis in many studies of acute myeloid leukaemia. A series of 54 patients treated at the Royal Marsden Hospital between 1979 and 1996, with APL and the t(15;17) chromosome translocation at pres‐entation, was examined for the effect of additional chromosome abnormalities in their presentation karyotype on survival.


Medical and Pediatric Oncology | 2001

Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study.

Tony Gordon; Aidan McManus; John Anderson; Toon Min; John Swansbury; Kathy Pritchard-Jones

BACKGROUND Rhabdomyosarcomas are the most common type of pediatric soft tissue sarcoma. The cytogenetic literature on RMS is biased towards the less common alveolar subtype (ARMS), which is frequently associated with specific translocations and the PAX3/7-FKHR fusion genes. Relatively few karyotypes are reported for the embryonal subtype (ERMS). The aim of this study was to further cytogenetic knowledge of RMS subtypes. PROCEDURE Representative examples of all karyotypes from UKCCG; member laboratories were reexamined and their histopathologies reviewed through the United Kingdom Childrens Cancer Study (Group) (UKCCSG). Molecular evidence for the PAX3/7-FKHR fusion genes was available for five ERMS and seven ARMS cases and compiled with the karyotypes. RESULTS Clonal chro mosome aberrations were characterized for 25 ERMS and 17 ARMS cases. Thirty-six percent of the ERMS cases involved translocation breakpoints in the 1p11-q11 region. Ten of the seventeen cases of ARMS showed cytogenetic evidence for the t(2;13)(q35;q14), consistent with molecular data available from four of these. Two further ARMS cases revealed a PAX3-FKHR and a variant PAX7-FKHR fusion gene product that were not detected cytogenetically. CONCLUSIONS Many of the karyotypes from both subtypes were complex. The frequent involvement of the 1p11-1q11 region and gain of chromosomes 2, 8, 12, and 13 in ERMS may be functionally significant. There was no evidence for involvement of the PAX3/7-FKHR genes in ERMS, and cryptic involvement was found in some ARMS. There were no consistent chromosomal rearrangements associated with apparently translocation negative ARMS cases.


Leukemia & Lymphoma | 2000

Disease Features in Acute Myeloid Leukemia with t(8;21)(q22;q22). Influence of Age, Secondary Karyotype Abnormalities, CD19 Status, and Extramedullar Leukemia on Survival

K. Rege; G. J. Swansbury; Atra A; C Horton; Toon Min; Melissa Dainton; E. Matutes; M. Durosinmi; J. Treleaven; R. Powles; Daniel Catovsky

Over a period of 14 years, 50 patients (12 children and 38 adults) of whom 46 had acute myeloid leukemia (AML) and 4 had myelodysplastic syndrome characterized by the t(8;21)(q22;q22) translocation were referred to the Royal Marsden Hospital. The clinico-pathological features of these cases were analyzed to determine the influence of age, secondary karyotype abnormalities, and expression of the lymphoid marker CD 19 on event free survival, and presence of extramedullary leukemia on overall survival. They were treated with a variety of chemotherapy protocols and some had bone marrow transplantation. There appeared to be no difference in survival between children (age >17 years) and adults (age >16 years). Out of the 50 cases, 16 (32%) had the (8;21) translocation alone, 17 (34 %) had additional loss of a sex chromosome and the remaining 17 (34%) had other karyotype abnormalities of which deletion or translocation of the long arms of a #9 was most common (observed in 8 of the 17 patients). The karyotype groups had a significant impact on survival, the group with loss of a sex chromosome having a poorer outcome and the group with abnormalities of chromosome 9 having a better outcome. CD19 positivity was seen in 21 of the 33 cases (63%) in whom it was measured compared to 11% observed in controls with AML without a t(8;21). CD19 status did not exert any influence on event free survival. Extramedullary leukemia (EML) occurred in 5 of the 50 cases (10%). In one patient it was observed at diagnosis but in the others it presented concurrent with bone marrow relapse. The overall survival of patients with EML was worse than that of the other patients but did not achieve statistical significance and was probably adversely affected by other factors.


Journal of Thoracic Oncology | 2011

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

Sanjay Popat; Alexandra Vieira de Araújo; Toon Min; John Swansbury; Melissa Dainton; Andrew Wotherspoon; Eric Lim; Andrew G. Nicholson; Mary O'Brien

A 65-year-old Caucasian female never-smoker ( 100 lifetime cigarettes) was found to have elevated carcinoembryonic antigen (CEA) after protracted gastrointestinal symptoms and underwent right lower lobectomy with systematic nodal dissection and pleural lavage for an asymptomatic 58-mm moderately differentiated TTF1positive lung adenocarcinoma with acinar pattern and nodal metastasis (pT2N2M0, stage IIIA). CEA normalized after surgery and she completed four cycles of adjuvant carboplatin and vinorelbine without major toxicities. Nine months after surgery, she developed a new 1.3-cm right upper lobe nodule and right hilar nodes with elevated CEA. Genotyping identified KRAS wild-type and EGFR exon 19 deletion in the primary tumor. She commenced systemic treatment with erlotinib at 150 mg daily and continued on this for 25 months with normalized CEA levels and a complete metabolic response on positron emission tomography-computed tomography (Figure 1). ALK rearrangement tested by fluorescence in situ hybridization (FISH) using the commercially available breakapart probe set (Abbott Molecular, Des Plaines, IL) demonstrated loss of the ALK 5 (centromeric) probe (Figure 2A). ALK immunohistochemistry (clone ALK1, Dako UK Ltd, DM828) was negative (Figure 2B).


The American Journal of Surgical Pathology | 2011

Primary Pulmonary Myxoid Sarcoma With EWSR1-CREB1 Fusion: A New Tumor Entity

Khin Thway; Andrew G. Nicholson; Kay Lawson; David Gonzalez; Alexandra Rice; Bonnie L. Balzer; John Swansbury; Toon Min; Lisa Thompson; Kwame Adu-Poku; Anne Campbell; Cyril Fisher

We present clinicopathologic data on 10 pulmonary myxoid sarcomas, which are defined by distinctive histomorphologic features and characterized by a recurrent fusion gene, that appear to represent a distinct tumor entity at this site. The patients [7 female, 3 male; aged 27 to 67 y (mean, 45 y)] presented with local or systemic symptoms (n=5), symptoms from cerebral metastasis (1), or incidentally (2). Follow-up of 6 patients showed that 1 with brain metastasis died shortly after primary tumor resection, 1 developed a renal metastasis but is alive and well, and 4 are disease free after 1 to 15 years. All tumors involved pulmonary parenchyma, with a predominant endobronchial component in 8 and ranged from 1.5 to 4 cm. Microscopically, they were lobulated and composed of cords of polygonal, spindle, or stellate cells within myxoid stroma, morphologically reminiscent of extraskeletal myxoid chondrosarcoma. Four cases showed no or minimal atypia, 6 showed focal pleomorphism, and 5 had necrosis. Mitotic indices varied, with most tumors not exceeding 5/10 high-power fields. Tumors were immunoreactive for only vimentin and weakly focal for epithelial membrane antigen. Of 9 tumors, 7 were shown to harbor a specific EWSR1-CREB1 fusion by reverse transcription-polymerase chain reaction and direct sequencing, with 7 of 10 showing EWSR1 rearrangement by fluorescence in situ hybridization. This gene fusion has been described previously in 2 histologically and behaviorally different sarcomas: clear cell sarcoma-like tumors of the gastrointestinal tract and angiomatoid fibrous histiocytomas; however, this is a novel finding in tumors with the morphology we describe and that occur in the pulmonary region.


Journal of Clinical Pathology | 2010

Utility of sarcoma-specific fusion gene analysis in paraffin-embedded material for routine diagnosis at a specialist centre

Khin Thway; Sasha Rockcliffe; David Gonzalez; John Swansbury; Toon Min; Lisa Thompson; Cyril Fisher

Aims Diagnosis of soft tissue sarcomas can be difficult. It can be aided by detection of specific genetic aberrations in many cases. This study assessed the utility of a molecular genetics/cytogenetics service as part of the routine diagnostic service at the Royal Marsden Hospital. Methods A retrospective audit was performed over a 15-month period to evaluate the diagnostic usefulness for soft tissue sarcomas with translocations of fluorescence in situ hybridisation (FISH) and reverse-transcriptase PCR (RT-PCR) in paraffin-embedded (PE) material. Results were compared with histology, and evaluated. Results Molecular investigations were performed on PE material in 158 samples (total 194 RT-PCR and 174 FISH tests), of which 85 were referral cases. Synovial sarcoma, Ewing sarcoma and low-grade fibromyxoid sarcoma were the most commonly tested tumours. Myxoid liposarcoma showed the best histological and molecular concordance, and alveolar rhabdomyosarcoma showed the best agreement between methods. FISH had a higher sensitivity for detecting tumours (73%, compared with 59% for RT-PCR) with a better success rate than RT-PCR, although the latter was specific in identifying the partner gene for each fusion. In particular, referral blocks in which methods of tissue fixation and processing were not certain resulted in higher RT-PCR failure rates. Conclusions FISH and RT-PCR on PE tissue are practical and effective ancillary tools in the diagnosis of soft tissue sarcomas. They are useful in confirming doubtful histological diagnoses and excluding malignant diagnoses. PCR is less sensitive than FISH, and the use of both techniques is optimal for maximising the detection rate of translocation-positive sarcomas.


Cancer Genetics and Cytogenetics | 1992

Inversion of chromosome 16 with the Philadelphia chromosome in acute myelomonocytic leukemia with eosinophilia: Report of two cases☆

Lorna M. Secker-Walker; Gareth J. Morgan; Toon Min; G. John Swansbury; Jeffrey M. Craig; Toshiyuki Yamada; L. Desalvo; J.W. Medina; Vij Chowdhury; Roger P. Donahue; Aaron Polliack; Daniel Catovsky

Two cases are described with the rare combination of inv(16)(p13q22), strongly associated with acute myelomonocytic leukemia with eosinophilia, M4Eo, and the Philadelphia translocation, t(9;22)(q34;q11), hallmark of chronic myeloid leukemia (CML) and rarely found, (less than 1%), in acute nonlymphocytic leukemia. The patients were: case 1, a 9-year-old girl presenting with a white blood cell count (WBC) 42 x 10(9)/L with 32% blasts and bone marrow with blasts and eosinophil precursors consistent with M4Eo, and case 2, a 25-year-old man with WBC 34.7 x 10(9)/L with 13% blasts and bone marrow with features of M4Eo and basophilia. Both patients achieved remission but died following bone marrow transplantation in first remission (case 1) or in relapse (case 2). Cytogenetic findings were: case 1, at diagnosis, 46,XX,inv(16)(p13q22)(21)/46,XX,t(9;22) (q34;q11),inv(16)(8)/46,XX(10), and case 2, at diagnosis, 46,XY,t(9;22) (q34;q11),inv(16)(p13q22) (16) and in remission, 46,XY,t(9;22)(q34;q11) (1)/46,XY (24). Investigation of the breakpoint on 22 in case 1 with Southern blotting and the polymerase chain reaction demonstrated the presence of a p190 mRNA and a breakpoint typical of acute leukemia. Thus a diagnosis of M4Eo was supported by clinical and cytogenetic sequelae in each case; the Ph in case 1 was apparently secondary to inv(16), in case 2 the Ph probably preceded inv(16) in the etiology of the leukemia.


Lung Cancer | 2012

ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Sanjay Popat; David Gonzalez; Toon Min; John Swansbury; Melissa Dainton; James Croud; Alexandra Rice; Andrew G. Nicholson

BACKGROUND ALK rearrangement is particularly observed in signet-ring sub-type adenocarcinoma. Since fluorescence in situ hybridization (FISH) is not suitable for mass screening, we aimed to characterize the predictive utility of tumour morphology and ALK immunoreactivity to identify ALK rearrangement, in a primary lung adenocarcinoma dataset enriched for signet-ring morphology, compared with that of other morphology. METHODS 7 adenocarcinomas from diagnostic archives reported with signet-ring morphology were assessed and compared with 11 adenocarcinomas without signet-ring features over the same time period. Growth patterns were reviewed, ALK expression was assessed by standard immunohistochemistry using ALK1 clone and Envision detection (Dako), and ALK rearrangement was assessed by FISH (Abbott Molecular). Associations between groups and predictive utility of tumour morphology and ALK expression using FISH as gold standard were calculated. RESULTS 2 excision lung biopsy cases with pure (100%) signet-ring morphology and solid patterns demonstrated diffuse moderate cytoplasmic ALK immunoreactivity (2+) and harboured ALK rearrangements (p=0.007), unlike 5 mixed-signet-ring and 11 non-signet-ring adenocarcinomas, which showed negative or 1+ immunoreactivity; and did not harbour ALK rearrangements (p>0.1). ALK expression was not associated with ALK copy number. 6 of 7 cases with signet ring morphology stained for TTF-1. Pure signet-ring morphology and moderate ALK expression were both associated with ALK rearranged tumours. CONCLUSION ALK rearrangement is strongly associated with ALK immunoreactivity, and was seen only in tumours with pure signet-ring morphology and solid growth pattern. Tumour morphology, growth pattern and ALK immunoreactivity appear to be good indicators of ALK rearrangement, with TTF-1 positivity aiding in proving primary pulmonary origin.


Genes, Chromosomes and Cancer | 1999

Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia.

Lionel J. Coignet; Carmen S Lima; Toon Min; Berthold Streubel; John Swansbury; Nicholas Telford; Soheila Swanton; Angela L. Bowen; Masami Nagai; Daniel Catovsky; Christa Fonatsch; Martin J. S. Dyer

Abnormalities of chromosome band 13q14 occur in hematologic malignancies of all lineages and at all stages of differentiation. Unlike other chromosomal translocations, which are usually specific for a given lineage, the chromosomal translocation t(12;13)(p12;q14) has been observed in both B‐cell and T‐cell precursor acute lymphoblastic leukemia (BCP‐, TCP‐ALL), in differentiated and undifferentiated acute myeloblastic leukemia (AML), and in chronic myeloid leukemia (CML) at progression to blast crisis. The nature of these translocations and their pathologic consequences remain unknown. To begin to define the gene(s) involved on chromosome 13, we have performed fluorescence in situ hybridization (FISH) using a panel of YACs from the region, on a series of 10 cases of acute leukemia with t(12;13)(p12;q14) and 1 case each with “variant” translocations including t(12;13)(q21;q14), t(10;13)(q24;q14) and t(9;13)(p21;q14). In 8/13 cases/cell lines, the 13q14 break fell within a single 1.4 Mb CEPH MegaYAC. This YAC fell immediately telomeric of the forkhead (FKHR) gene, which is disrupted in the t(2;13)(q35;q14) seen in pediatric alveolar rhabdomyosarcoma. Seven of the 8 cases with breaks in this YAC were AML. In 4/13 cases, the 13q14 break fell within a 1.7‐Mb YAC located about 3 Mb telomeric of the retinoblastoma (RB1) gene: all 4 cases were ALL. One case of myelodysplastic syndrome exhibited a break within 13q12, adjacent to the BRCA2 gene. These data indicate the presence of myeloid‐ and lymphoid‐specific breakpoint cluster regions within chromosome band 13q14 in acute leukemia. Genes Chromosomes Cancer 25:222–229, 1999.


Leukemia & Lymphoma | 2004

Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings

Caroline L. Alvares; Estella Matutes; Marie A Scully; John Swansbury; Toon Min; Alicja M. Gruszka-Westwood; Shayne Atkinson; Benjamin L. Hilditch; Ricardo Morilla; Andrew Wotherspoon; Daniel Catovsky

Diffuse large B cell lymphoma (DLBL) comprises a heterogenous entity characterized by the presence of large cells, exhibiting a mature B cell phenotype. The high proliferation rate and aggressive disease remain a therapeutic challenge, but the apparent biological diversity permits a risk-stratification model for prognostic grouping through the International Prognostic Index (IPI). Empirical to this approach is the consideration of cytogenetic data, offering an insight into the pathogenetic events which may underlie neoplastic clonal evolution and disease progression. We describe three cases of DLBL presenting with isolated marrow disease, a rare primary finding in this lymphoma. All three cases showed involvement of blood and bone marrow without evidence of splenic or lymph node involvement on imaging studies. Histological and immunophenotypic findings were similar in all three cases, outlining the phenotypic maturity of this disease. Cytogenetic analysis revealed complex karyotypes in the two cases examined. M-FISH (multicolour fluorescent in situ hybridization) performed on bone marrow from case 1 showed several cryptic translocations not evident on G-banding, including a novel translocation between 2p and 9p, and an unbalanced translocation between 14q and 11q. Cytogenetic analysis in case 2 showed abnormalities involving 7q, 9p at the site of the INK4a gene, and the bcl-2 locus, findings confirmed by M-FISH. These cases serve to highlight the biological and cytogenetic heterogenity of DLBL and emphasize the need for complementary investigations in the characterization of this entity.

Collaboration


Dive into the Toon Min's collaboration.

Top Co-Authors

Avatar

John Swansbury

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Daniel Catovsky

Institute of Cancer Research

View shared research outputs
Top Co-Authors

Avatar

R. Powles

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

David Gonzalez

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

G. J. Swansbury

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

J. Treleaven

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Gareth J. Morgan

University of Arkansas for Medical Sciences

View shared research outputs
Top Co-Authors

Avatar

Andrew Wotherspoon

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Cyril Fisher

The Royal Marsden NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Estella Matutes

The Royal Marsden NHS Foundation Trust

View shared research outputs
Researchain Logo
Decentralizing Knowledge